The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 29, 2025

Filed:

Oct. 04, 2021
Applicant:

Adicet Therapeutics, Inc., Redwood City, CA (US);

Inventors:

Aya Jakobovits, Beverly Hills, CA (US);

Orit Foord, Foster City, CA (US);

Andy An-Deh Lin, Palo Alto, CA (US);

Marianne Theresa Santaguida, Belmont, CA (US);

Assignee:

ADICET THERAPEUTICS, INC., Redwood City, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2025.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); C12N 15/00 (2006.01); C07K 14/74 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0636 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61K 40/4205 (2025.01); A61K 40/4211 (2025.01); A61K 40/4212 (2025.01); A61K 40/4222 (2025.01); A61K 40/4255 (2025.01); A61K 40/4266 (2025.01); A61K 40/4274 (2025.01); C07K 14/70503 (2013.01); C12N 15/00 (2013.01); C07K 14/70539 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/515 (2013.01); C12N 2501/599 (2013.01); C12N 2501/999 (2013.01);
Abstract

The present invention relates to engineered γδ T-cell(s) and methods for using the same as a therapeutic with a potent and selective ability to target an antigen of choice. Engineered γδ T-cells of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders. Also disclosed are methods for expanding engineered and non-engineered γδ T-cell(s) populations to therapeutically useful quantities. An engineered γδ T-cell of the disclosure can be a universal donor, and can be administered to a subject with any MHC haplotype.


Find Patent Forward Citations

Loading…